Methods and kits for measuring von Willebrand factor
View Patent ↗Methods and kits for measuring levels of von Willebrand factor function in a sample without using a platelet aggregation agonist, such as ristocetin, comprising recombinant glycoprotein Ibα having at least two of a G233V, D235Y and M239V mutations and an agent to detect a complex between the recombinant glycoprotein Ibα and von Willebrand factor.
1. A method of measuring von Willebrand factor (VWF) without using a platelet agglutination agonist, the method comprising the steps of:
providing a surface comprising immobilized platelet glycoprotein Ibα (GPIbα) or a functional fragment thereof, wherein the immobilized GPIbα or functional fragment thereof comprises at least two mutations selected from the group consisting of G233V, D235Y and M239V relative to SEQ ID NO: 11, wherein one of the mutations is D235Y;
contacting a sample having or suspected of having VWF with the surface, wherein the contacting is done without a platelet aggregation agonist; and
measuring a complex of VWF and GPIbα.
2. The method of claim 1 , wherein the surface is a host cell surface, and wherein the host cell does not natively express GPIbα.
3. The method of claim 2 , wherein the host cell for the host cell surface is selected from the group consisting of a Xenopus oocyte, a CHO-K1 cell, a L929 cell, a HEK-293T cell, a COS-7 cell and a S2 cell, and wherein the host cell is engineered to comprise a polynucleotide encoding GPIbα or functional fragment thereof having the at least two mutations selected from the group consisting of G233V, D235Y and M239V relative to SEQ ID NO: 11.
4. The method of claim 2 , wherein the host cell surface also comprises glycoprotein Ibβ (GPIbβ) and optionally glycoprotein IX (GP-IX), wherein GPIbβ comprises SEQ ID NO:4 and GP-IX comprises SEQ ID NO:8.
5. The method of claim 1 , wherein the surface is a solid-phase surface selected from the group consisting of agarose, glass, latex and plastic.
6. The method of claim 5 , wherein the solid-phase surface comprises an anti-GPIbα antibody that binds the GPIbα or functional fragment thereof.
7. The method of claim 1 , wherein the sample is plasma.
8. The method of claim 1 , wherein the at least two mutations are selected from the group consisting of D235Y/G233V and D235Y/M239V.
9. A method of measuring von Willebrand factor (VWF) without using a platelet agglutination agonist, the method comprising the steps of:
providing a surface comprising immobilized platelet glycoprotein Ibα (GPIbα) or a functional fragment thereof, wherein the immobilized GPIbα or functional fragment thereof comprises at least two mutations selected from the group consisting of G233V, D235Y and M239V relative to SEQ ID NO: 11, wherein the at least two mutations are D235Y/G233V/M239V;
contacting a sample having or suspected of having VWF with the surface, wherein the contacting is done without a platelet aggregation agonist; and
measuring a complex of VWF and GPIbα.
10. The method of claim 1 , wherein a labeled anti-VWF antibody is used to detect the complex of VWF and GPIbα.
11. A kit for measuring active von Willebrand factor (VWF), the kit comprising:
recombinant platelet glycoprotein Ibα (GPIbα) or a functional fragment thereof, wherein the GPIbα or functional fragment thereof comprises at least two mutations selected from the group consisting of G233V, D235Y and M239V relative to SEQ ID NO: 11, wherein one of the mutations is D235Y; and
a reagent to detect a complex of VWF and GPIbα.
12. The kit of claim 11 , wherein the reagent is a labeled anti-VWF antibody.
13. The kit of claim 11 , further comprising a control, wherein the control is a plasma sample from an individual that does not have von Willebrand disease (VWD).
14. The kit of claim 11 , wherein the GPIbα or functional fragment thereof having the at least two mutations selected from the group consisting of G233V, D235Y and M239V relative to SEQ ID NO: 11, wherein one of the mutations is D235Y, is immobilized on a surface.
15. The kit of claim 14 , wherein the surface is a host cell surface, and wherein the host cell does not natively express GPIbα.
16. The kit of claim 15 , wherein the host cell for the host cell surface is selected from the group consisting of a Xenopus oocyte, a CHO-K1 cell, a L929 cell, a HEK-293T cell, a COS-7 cell and a S2 cell, and wherein the host cell is engineered to comprise a polynucleotide encoding GPIbα or functional fragment thereof having the at least two mutations selected from the group consisting of G233V, D235Y and M239V relative to SEQ ID NO: 11, wherein one of the mutations is D235Y.
17. The kit of claim 15 , wherein the host cell surface also comprises glycoprotein Ibβ (GPIbβ) and optionally glycoprotein IX (GP-IX), wherein GPIbβ comprises SEQ ID NO:4 and GP-IX comprises SEQ ID NO:8.
18. The kit of claim 14 , wherein the surface is a solid-phase surface selected from the group consisting of agarose, glass, latex and plastic.
19. The kit of claim 18 , wherein the solid-phase surface comprises an anti-GPIbα antibody that binds to GPIbα or functional fragment thereof.
20. The kit of claim 11 , wherein the at least two mutations are selected from the group consisting of D235Y/G233V, D235Y/M239V and D235Y/G233V/M239V.